Skip to main content

Clinical Trials › NCT06846281

RecruitingPhase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Sponsored by Novartis Pharmaceuticals

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
360
Target enrollment
18
U.S. states
Jul 2025
Start date
Jun 2031
Expected completion

Interventions / Treatments

Remibrutinib oral treatmentOcrelizumab

Conditions studied

Relapsing Multiple Sclerosis

Where this trial is running (33 sites)

Florida8 sites
Altamonte Springs · Gainesville · Maitland · +5 more
Texas4 sites
Austin · Dallas · Fort Worth · +1 more
Boston · Burlington · Foxborough
Ohio3 sites
Centerville · Cincinnati · Columbus
Michigan2 sites
Farmington Hills · Owosso
Arizona1 site
Scottsdale
Washington D.C.
Illinois1 site
Chicago
Kansas1 site
Kansas City
Maryland1 site
Olney
Missouri1 site
St Louis
Teaneck
Albuquerque
Raleigh
Fargo
Greenville
Tennessee1 site
Knoxville
Wisconsin1 site
Greenfield

MS centers in Florida

Compare treatment centers near a trial site by center type, providers and trials.

View Florida centers

More Phase 3 trials

Browse all Phase 3 MS trials
The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play